Table 2.
Parameters | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Subtype TNBC vs non-TNBC |
1.213 | 0.577–2.550 | 0.611 | 0.849 | 0.387–1.861 | 0.683 |
Subtype HER2+BC vs non-HER2+BC |
0.421 | 0.147–1.206 | 0.107 | 0.552 | 0.181–1.686 | 0.297 |
Lymph node status Positive vs negative |
4.157 | 0.990–17.456 | 0.052 | 4.330 | 1.027–18.263 | 0.046 |
Pathological response pCR vs Non-pCR |
0.611 | 0.279–1.336 | 0.217 | 0.854 | 0.352–2.072 | 0.728 |
PD-1 Positive vs negative |
2.752 | 1.300–5.826 | 0.008 | 1.415 | 0.526–3.811 | 0.492 |
PD-L1 Positive vs negative |
3.194 | 1.544–6.607 | 0.002 | 2.613 | 0.879–7.766 | 0.084 |
CI confidence interval, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand